Press Releases

Press Releases

Date Title and Summary Additional Formats
Toggle Summary Ziopharm Oncology Appoints Four Additional Members to Scientific Advisory Board
BOSTON , Sept. 15, 2020 (GLOBE NEWSWIRE) -- Ziopharm Oncology , Inc. (“Ziopharm” or “the Company”) (Nasdaq: ZIOP), today announced the appointment of four additional members to its Scientific Advisory Board (SAB). The SAB , under the leadership of Carl June , M.D.
View HTML
Toggle Summary Ziopharm Oncology Granted Rare Pediatric Disease Designation for Controlled IL-12 for the Treatment of DIPG
BOSTON , Sept. 14, 2020 (GLOBE NEWSWIRE) -- Ziopharm Oncology , Inc. (“Ziopharm” or “the Company”) (Nasdaq:ZIOP) today announced that the U.S. Food and Drug Administration (FDA) has granted Rare Pediatric Disease Designation to Ad-RTS-hIL-12 with veledimex (Controlled IL-12) for the investigational
View HTML
Toggle Summary Ziopharm Oncology to Participate in Upcoming Conferences
BOSTON , Sept. 10, 2020 (GLOBE NEWSWIRE) -- Ziopharm Oncology , Inc. (Nasdaq: ZIOP), today announced that Laurence Cooper , M.D., Ph.D., Chief Executive Officer of Ziopharm, is scheduled to participate in two upcoming conferences: H.C. Wainwright 22nd Annual Global Investment Conference   Date:  
View HTML
Toggle Summary Ziopharm Oncology Reports Second Quarter 2020 Financial Results and Provides Corporate Update
– Enrollment completed in Controlled IL-12 phase 2 clinical trial with Regeneron’s Libtayo ® – – First patient with DIPG dosed in phase 1/2 pediatric brain tumor trial of Contolled IL-12 – – Work restrictions at the NCI and MD Anderson easing; MD Anderson initiated phase 1 CD19-specific CAR-T
View HTML
Toggle Summary Ziopharm Oncology to Report Second Quarter 2020 Financial Results and Host a Conference Call and Webcast on August 6, 2020
BOSTON , July 28, 2020 (GLOBE NEWSWIRE) -- Ziopharm Oncology , Inc. (Nasdaq: ZIOP), today announced the Company will host a conference call and webcast on Thursday, August 6 , at 4:30 pm EDT to provide a corporate update and discuss financial results for the second quarter ended June 30, 2020 .
View HTML
Toggle Summary Ziopharm Oncology Names James Huang to Board of Directors
– Industry veteran entrepreneur with 20+ years’ experience founding and financing successful, innovative biotech companies including GenScript and Legend Biotech   – Managing Partner at Kleiner Perkins Caufield & China; Founder of Panacea Venture, funding source for Ziopharm’s joint venture
View HTML
Toggle Summary Ziopharm Oncology Announces Initiation of Phase 1 Trial Evaluating Rapid Personalized Manufacturing CAR-T Technology in Patients with Relapsed CD19+ Leukemias and Lymphomas
- RPM leverages the Sleeping Beauty system to reduce cost and simplify production for CD19-specific CAR-T infusion the day after gene transfer - BOSTON , July 09, 2020 (GLOBE NEWSWIRE) -- Ziopharm Oncology , Inc. (“Ziopharm” or “the Company”) (Nasdaq:ZIOP), today announced the initiation of a phase
View HTML
Toggle Summary Ziopharm Oncology Doses First DIPG Patient in Phase 1/2 Trial of Controlled IL-12 for the Treatment of Pediatric Brain Tumors
BOSTON , July 08, 2020 (GLOBE NEWSWIRE) -- Ziopharm Oncology , Inc. (“Ziopharm” or “the Company”) (Nasdaq:ZIOP) today announced that the first patient with diffuse intrinsic pontine glioma (DIPG) has been dosed in its phase 1/2 study of Ad-RTS-hIL-12 with veledimex (Controlled IL-12) for the
View HTML
Toggle Summary Ziopharm Oncology Completes Enrollment of Phase 2 Trial Evaluating Controlled IL-12 in Combination with Libtayo® in Patients with Glioblastoma
BOSTON , June 22, 2020 (GLOBE NEWSWIRE) -- Ziopharm Oncology , Inc. (“Ziopharm” or “the Company”) (Nasdaq:ZIOP) today announced that 36 subjects have been enrolled in the phase 2 clinical trial evaluating Ad-RTS-hIL-12 with veledimex (Controlled IL-12) in combination with the PD-1 inhibitor Libtayo
View HTML
Toggle Summary Ziopharm Oncology Appoints Carl June, M.D., as Chairman of Scientific Advisory Board
BOSTON , June 15, 2020 (GLOBE NEWSWIRE) -- Ziopharm Oncology , Inc. (“Ziopharm” or “the Company”) (Nasdaq: ZIOP), today announced the appointment of renowned oncology and immunotherapy pioneer, Carl June , M.D., as Chairman of its newly formed Scientific Advisory Board (SAB). Dr.
View HTML